查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1714878

过敏免疫疗法市场按治疗类型、过敏原类型、免疫疗法交付模式、技术平台、过敏类型、最终用户、分销管道划分 - 2025 年至 2030 年全球预测

Allergy Immunotherapy Market by Treatment Type, Allergen Type, Immunotherapy Delivery Form, Technology Platform, Allergy Type, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计过敏免疫疗法市场规模在 2024 年将达到 18.6 亿美元，在 2025 年将达到 20.4 亿美元，在 2030 年将达到 33 亿美元，复合年增长率为 10.03%。

主要市场统计数据
基准年2024年 18.6亿美元
预计2025年 20.4亿美元
预测年份 2030 33亿美元
复合年增长率（%） 10.03%

过敏免疫疗法是一种控制并可能抑制全球过敏性疾病传播的创新方法。在过去的几十年里，从传统的症状治疗到针对潜在免疫反应的介入治疗，已经取得了巨大的进展。这种演变是由对免疫机制的更深入理解、分子生物学的创新研究以及新治疗技术的采用所推动的。当前市场的特点是临床研究、新技术平台和过敏性疾病日益流行的动态相互作用。这些快速发展迫使决策者和临床专家重新审视传统的治疗模式。本书是一本全面的概述，深入探讨了过敏免疫治疗领域的多方面方面，并描绘了其充满挑战但充满希望的发展轨迹。本书着重资料驱动的洞察力和可操作的相关性，批判性地分析市场并帮助相关人员清楚地了解当前趋势和未来机会。

改变过敏免疫疗法市场

过敏免疫治疗领域的最新变化正在重新定义相关人员如何看待和管理过敏性疾病。在尖端研究和先进诊断技术的推动下，市场正在从反应性和对症治疗转向预防和治疗策略。这种转变是由几个关键因素推动的，包括增强生物标记发现、标靶递送系统的发展以及对个人化治疗的日益关注。由于临床试验显示出良好的结果，监管机构也开始重新评估安全性和有效性标准，以便快速引入新的治疗方法。技术的引入，尤其是基于奈米技术的平台和基因改造过敏原的开发，透过精确调节免疫反应来改善患者的治疗效果。此外，病患监测系统和资料分析的改进正在增强治疗方案并促进更具适应性和回应性的管理。这种演变促使人们重新评估投资重点，并为研究机构、生物製药公司和医疗保健提供者之间的合作铺平道路，以确保科学突破转化为改善的患者照护和市场成长。

多面向分析关键环节

对过敏免疫疗法市场的详细分析揭示了复杂而细微的细分结构，有助于有标靶治疗开发和准确的市场评估。依治疗类型分为表皮免疫治疗、口服免疫治疗、皮下免疫治疗、舌下免疫治疗，各治疗方式的侵袭性和患者依从性均有不同。考虑过敏原的类型时，它们包括动物皮屑、尘螨、食物过敏原和花粉。食物过敏原深入研究鸡蛋过敏原、牛奶过敏原、花生过敏原和树坚果过敏原的细微差别，每种过敏原都有其特异性的免疫学特征和患者反应。也重点关注给药形式——皮肤贴片、输液、注射或锭剂——以评估该形式是否适合治疗效果和患者偏好。对技术平台的分析揭示了从传统佐剂到复杂的基于奈米技术的平台甚至转基因过敏原的广泛频谱，预示着精准免疫疗法新时代的到来。此外，依过敏类型分类，过敏性气喘、过敏性鼻炎、异位性皮肤炎、荨麻疹等都是重要的治疗领域。市场细分可以将最终用户进一步细分为居家照护、医院、研究和学术实验室以及专科诊所环境，以详细了解需求动态。最后，医院药局、网路药局和零售药局等分销管道确保所采用的治疗药物有效地到达消费者手中，同时保持高标准的合规性和安全性。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 过敏性疾病盛行率的上升推动了对过敏免疫治疗解决方案的需求
      • 政府措施和有利的医疗政策支持免疫疗法整合
      • 人们对过敏症的认识和诊断不断提高，促进了对创新治疗方法的需求。
    • 限制因素
      • 过敏免疫疗法的高开发成本限制了患者和医疗保健系统的可近性
    • 机会
      • 开发过敏免疫治疗解决方案，以解决在多个地区普遍存在的交叉反应过敏原
      • 扩大远距咨询和远端医疗过敏护理服务数位平台的潜力
    • 任务
      • 严格的法规结构和冗长的新产品上市核准流程
  • 市场区隔分析
    • 治疗类型：舌下免疫疗法在治疗花粉和尘螨过敏方面的需求不断增长
    • 最终用户：过敏免疫疗法在管理慢性过敏的医院中的重要性日益增加
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 过敏免疫疗法市场（依治疗类型）

  • 皮下免疫治疗
  • 口服免疫疗法
  • 皮下免疫治疗
  • 舌下免疫治疗

7. 过敏免疫治疗市场（依过敏原型）

  • 动物皮屑
    • 猫过敏原
    • 狗过敏原
  • 打钩
  • 食物过敏原
    • 鸡蛋过敏原
    • 牛奶过敏原
    • 花生过敏原
    • 树坚果过敏原
  • 花粉

8. 过敏免疫治疗市场免疫治疗给药形式

  • 皮肤贴片
  • 降低
  • 注射
  • 药片

9. 过敏免疫治疗市场技术平台

  • 佐剂
  • 基于奈米技术的平台
  • 重组过敏原

第 10 章 过敏免疫治疗市场（依过敏类型）

  • 过敏性气喘
  • 过敏性鼻炎
  • 异位性皮肤炎
  • 麻疹

第 11 章过敏免疫疗法市场（按最终用户）

  • 居家照护环境
  • 医院
  • 研究与学术研究所
  • 专科诊所

第 12 章过敏免疫治疗市场（按通路）

  • 医院药房
  • 网路药局
  • 零售药局

13. 美洲过敏免疫疗法市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

14. 亚太地区过敏免疫治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

15. 欧洲、中东和非洲过敏免疫治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十六章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Adamis Pharmaceuticals Corporation
  • ALK-Abello, Inc.
  • Allergy Therapeutics PLC
  • Anergis SA
  • ASIT Biotech by DMS Imaging
  • ASIT Biotech SA
  • Biomay AG
  • Biomunex Pharmaceuticals SAS
  • BioSpace, Inc.
  • Circassia Group PLC
  • DBV Technologies SA
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • HAL Allergy BV
  • HollisterStier Allergy by Jubilant Pharma Company
  • Jubilant HollisterStier LLC
  • LETI Pharma, SLU
  • Merck KGaA
  • Mylan NV by Viatris Inc.
  • NOVARTIS AG
  • Sanofi SA
  • Stallergenes Greer International AG
  • Stallergenes Greer Ltd
  • Torii Pharmaceutical Co., Ltd.
Product Code: MRR-436901065A53

The Allergy Immunotherapy Market was valued at USD 1.86 billion in 2024 and is projected to grow to USD 2.04 billion in 2025, with a CAGR of 10.03%, reaching USD 3.30 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.86 billion
Estimated Year [2025] USD 2.04 billion
Forecast Year [2030] USD 3.30 billion
CAGR (%) 10.03%

Allergy immunotherapy represents a transformative approach in managing and potentially curbing the prevalence of allergic disorders across the globe. In the past decades, significant strides have been made from traditional symptomatic treatments to interventions that address the underlying immune responses. This evolution is driven by a deeper understanding of immunological mechanisms, innovative research in molecular biology, and the adoption of novel therapeutic techniques. The current market is characterized by a dynamic interplay of clinical research, emerging technology platforms, and an increasing prevalence of allergic conditions. Decision-makers and clinical experts alike are now prompted to re-examine conventional treatment paradigms in the light of these rapid developments. This comprehensive overview provides an in-depth narrative that examines the multi-dimensional aspects of the allergy immunotherapy sector, charting a trajectory that is as promising as it is challenging. With a measured focus on data-driven insights and practical relevance, this document sets the stage for a critical analysis of the market, empowering stakeholders with a clear understanding of both current trends and future opportunities.

Transformative Shifts in the Allergy Immunotherapy Landscape

Recent transformative changes in the allergy immunotherapy arena have redefined how stakeholders view and manage allergic conditions. Driven by cutting-edge research and the integration of advanced diagnostics, the market is experiencing a shift from reactive and symptomatic treatments to proactive and curative strategies. These shifts are underpinned by several key factors, including enhanced biomarker discovery, the development of targeted delivery systems, and an increased focus on personalized treatments. As clinical trials deliver promising outcomes, regulatory bodies have also begun to revisit the safety and efficacy benchmarks, allowing expedited pathways for newer therapies. The infusion of technology, particularly in nanotechnology-based platforms and recombinant allergen development, is creating better patient outcomes by precisely modulating immune responses. Furthermore, improved patient monitoring systems and data analytics have fortified the treatment protocols, fostering a more adaptive and responsive management framework. This evolution has prompted a reevaluation of investment priorities and has paved the way for collaborations across research institutes, biopharmaceutical companies, and healthcare providers, ensuring that breakthroughs in science translate to enhanced patient care and market growth.

Key Segmentation Insights Across Multiple Dimensions

In-depth analysis of the allergy immunotherapy market unveils a complex and nuanced segmentation structure that facilitates targeted therapy development and precise market assessments. An exploration of treatment types reveals the inclusion of Epicutaneous Immunotherapy, Oral Immunotherapy, Subcutaneous Immunotherapy, and Sublingual Immunotherapy, each offering varying degrees of invasiveness and patient compliance. When considering allergen types, the studies extend to encompass Animal Dander, Dust Mites, Food Allergens, and Pollen. Notably, Animal Dander further subdivides into dynamics associated with Cat Allergens and Dog Allergens, while Food Allergens delve into the subtleties of Egg Allergens, Milk Allergens, Peanut Allergens, and Tree Nut Allergens, each presenting specific immunological profiles and patient responses. There is also a keen focus on delivery forms where modalities such as Dermal Patch, Drops, Injections, and Tablets are evaluated, ensuring that the form factor aligns with the therapeutic efficacy and patient preference. Analyzing technology platforms reveals a spectrum that ranges from conventional Adjuvants to sophisticated Nanotechnology-Based Platforms and even Recombinant Allergens which herald a new era of precision immunotherapy. In addition, categorizing based on allergy type, the market identifies Allergic Asthma, Allergic Rhinitis, Atopic Dermatitis, and Urticaria as critical therapeutic areas. Market studies further segment based on end-users, including the environments of Homecare Settings, Hospitals, Research & Academic Laboratories, and Specialty Clinics, thereby enabling a granular understanding of demand dynamics. Finally, the distribution channels - spanning Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy - ensure that the adopted therapies reach consumers effectively while maintaining high standards of compliance and safety.

Based on Treatment Type, market is studied across Epicutaneous Immunotherapy, Oral Immunotherapy, Subcutaneous Immunotherapy, and Sublingual Immunotherapy.

Based on Allergen Type, market is studied across Animal Dander, Dust Mites, Food Allergens, and Pollen. The Animal Dander is further studied across Cat Allergens and Dog Allergens. The Food Allergens is further studied across Egg Allergens, Milk Allergens, Peanut Allergens, and Tree Nut Allergens.

Based on Immunotherapy Delivery Form, market is studied across Dermal Patch, Drops, Injections, and Tablets.

Based on Technology Platform, market is studied across Adjuvants, Nanotechnology-Based Platforms, and Recombinant Allergens.

Based on Allergy Type, market is studied across Allergic Asthma, Allergic Rhinitis, Atopic Dermatitis, and Urticaria.

Based on End User, market is studied across Homecare Settings, Hospitals, Research & Academic Laboratories, and Specialty Clinics.

Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.

Key Regional Insights Driving Market Growth

Regional dynamics play a crucial role in shaping the strategies and investments within the allergy immunotherapy market. In the Americas, a combination of advanced healthcare infrastructure, rapid adoption of innovative therapeutics, and a high prevalence of allergic conditions have spurred considerable market activity. Researchers and investors in this region benefit from robust clinical research networks and a government framework that is increasingly supportive of novel therapeutic approaches. Across Europe, the Middle East, and Africa, regulatory reforms and a significant push towards preventive healthcare have laid the groundwork for accelerated market penetration. This region is characterized by strategic collaborations between academic entities and clinical establishments, which facilitate the seamless translation of research insights into marketable solutions. Meanwhile, the Asia-Pacific region has emerged as a significant contributor to the global market, driven by a large population base, increasing urbanization, and a rising awareness about the benefits of modern immunotherapy treatments. Healthcare reforms, improved insurance coverage, and a growing emphasis on personalized medicine are catalyzing the adoption of cutting-edge immunotherapy solutions in this region. These regional insights underscore a market that is not only diverse but also adaptive to the unique healthcare needs and regulatory environments of different geographies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Shaping the Industry Landscape

The allergy immunotherapy industry is marked by the active participation of several key players whose innovations and market strategies have significantly influenced the industry's trajectory. Major industry participants include Adamis Pharmaceuticals Corporation, ALK-Abello, Inc., and Allergy Therapeutics PLC, whose efforts in research and development have led to breakthrough therapies. Noteworthy contributions also come from Anergis SA and ASIT Biotech by DMS Imaging, entities that have continually pushed boundaries in treatment modalities. Organizations such as ASIT Biotech SA have reinforced their market presence with dedicated studies and technology transfer, contributing valuable insights into immunotherapy delivery methods. Additionally, Biomay AG and Biomunex Pharmaceuticals SAS have specialized in developing novel platforms that harness the power of molecular biology. The market also sees innovative input from BioSpace, Inc. and Circassia Group PLC, whose comprehensive solutions have been integral in bridging clinical research with patient-centric care. Pioneering advancements by DBV Technologies SA, complemented by the extensive research and development pipelines of pharmaceutical giants like Eli Lilly and Company and F. Hoffmann-La Roche Ltd., have set a benchmark for scientific excellence. Furthermore, the influence of GlaxoSmithKline plc, HAL Allergy B.V., and HollisterStier Allergy by Jubilant Pharma Company, as well as contributions from Jubilant HollisterStier LLC and LETI Pharma, S.L.U., underscore the dynamic interplay of innovation and market strategy. The industry also continues to benefit from the forward-thinking strategies of Merck KGaA, Mylan N.V. by Viatris Inc., NOVARTIS AG, Sanofi S.A, Stallergenes Greer International AG, Stallergenes Greer Ltd, and Torii Pharmaceutical Co., Ltd., all of which have played pivotal roles in expanding therapeutic options and enhancing safety profiles across multiple segments.

The report delves into recent significant developments in the Allergy Immunotherapy Market, highlighting leading vendors and their innovative profiles. These include Adamis Pharmaceuticals Corporation, ALK-Abello, Inc., Allergy Therapeutics PLC, Anergis SA, ASIT Biotech by DMS Imaging, ASIT Biotech SA, Biomay AG, Biomunex Pharmaceuticals SAS, BioSpace, Inc., Circassia Group PLC, DBV Technologies SA, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, HAL Allergy B.V., HollisterStier Allergy by Jubilant Pharma Company, Jubilant HollisterStier LLC, LETI Pharma, S.L.U., Merck KGaA, Mylan N.V. by Viatris Inc., NOVARTIS AG, Sanofi S.A, Stallergenes Greer International AG, Stallergenes Greer Ltd, and Torii Pharmaceutical Co., Ltd.. Actionable Recommendations for Industry Leaders

Industry leaders are encouraged to adopt a multifaceted strategic approach as the market for allergy immunotherapy continues to evolve. Firstly, investing in advanced research and integrating innovative diagnostic technologies can significantly bolster the efficacy of currently available treatments. Leaders should actively seek collaborations with research institutions and technology providers to harness the potential of nanotechnology-based platforms and recombinant allergen strategies. Additionally, optimizing the supply chain through enhanced coordination with distribution channels - whether hospital, online, or retail pharmacies - can ensure that breakthroughs in immunotherapy reach patients swiftly and safely. A forward-thinking approach also involves aligning with regulatory bodies to facilitate faster approval processes and streamline market entry. Embracing data-driven decision-making, through comprehensive market analytics, will empower companies to adapt to changing consumer demands and regional market dynamics. Proactive measures such as expanding clinical trial networks across diverse geographic regions, particularly in areas with high growth potential, can yield valuable insights that guide strategic investments. Finally, industry leaders are urged to foster patient-centric care models, ensuring that treatment regimens are tailored to individual needs without compromising on safety or efficacy. By maintaining a balance between innovative therapy development and robust operational strategies, decision-makers can secure a competitive advantage and drive sustainable growth in the allergy immunotherapy sector.

Conclusion: Charting the Path Forward in Allergy Immunotherapy

To conclude, the landscape of allergy immunotherapy is undergoing significant transformation as a result of technological advancements, progressive clinical research, and shifting consumer expectations. Through a careful synthesis of evolving treatment protocols and innovative delivery systems, the market is poised for a new era of precision medicine that mitigates the impact of allergic conditions while enhancing the quality of life for patients. This comprehensive overview has delved into the intricacies of market segmentation, regional variances, and the roles of top industry players, underscoring the importance of an integrated and informed approach. As policymakers, clinicians, and industry leaders align their strategies with emerging trends, the focus remains steadfast on fostering innovation, ensuring regulatory compliance, and ultimately delivering effective and sustainable therapy outcomes. The journey ahead is characterized by both challenges and opportunities, and the commitment to continuous improvement will be the cornerstone of future success in managing allergic disorders on a global scale.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of allergic conditions raises demand for allergy immunotherapy solutions
      • 5.1.1.2. Government initiatives and favorable healthcare policies supporting the integration of immunotherapy
      • 5.1.1.3. Increasing awareness and diagnosis of allergies contributes to the demand for innovative treatments
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of developing allergy immunotherapy limits accessibility for patients and healthcare systems
    • 5.1.3. Opportunities
      • 5.1.3.1. Developing allergy immunotherapy solutions addressing cross-reactive allergens prevalent in multiple regions
      • 5.1.3.2. Expansion potential of digital platforms for remote consultations and telehealth allergy care services
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory frameworks and lengthy approval processes for new product launches
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Rising need for sublingual immunotherapy for treating pollen and dust mite allergies
    • 5.2.2. End User: Growing significance of allergy immunotherapy in hospitals to manage chronic allergies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Allergy Immunotherapy Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Epicutaneous Immunotherapy
  • 6.3. Oral Immunotherapy
  • 6.4. Subcutaneous Immunotherapy
  • 6.5. Sublingual Immunotherapy

7. Allergy Immunotherapy Market, by Allergen Type

  • 7.1. Introduction
  • 7.2. Animal Dander
    • 7.2.1. Cat Allergens
    • 7.2.2. Dog Allergens
  • 7.3. Dust Mites
  • 7.4. Food Allergens
    • 7.4.1. Egg Allergens
    • 7.4.2. Milk Allergens
    • 7.4.3. Peanut Allergens
    • 7.4.4. Tree Nut Allergens
  • 7.5. Pollen

8. Allergy Immunotherapy Market, by Immunotherapy Delivery Form

  • 8.1. Introduction
  • 8.2. Dermal Patch
  • 8.3. Drops
  • 8.4. Injections
  • 8.5. Tablets

9. Allergy Immunotherapy Market, by Technology Platform

  • 9.1. Introduction
  • 9.2. Adjuvants
  • 9.3. Nanotechnology-Based Platforms
  • 9.4. Recombinant Allergens

10. Allergy Immunotherapy Market, by Allergy Type

  • 10.1. Introduction
  • 10.2. Allergic Asthma
  • 10.3. Allergic Rhinitis
  • 10.4. Atopic Dermatitis
  • 10.5. Urticaria

11. Allergy Immunotherapy Market, by End User

  • 11.1. Introduction
  • 11.2. Homecare Settings
  • 11.3. Hospitals
  • 11.4. Research & Academic Laboratories
  • 11.5. Specialty Clinics

12. Allergy Immunotherapy Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Hospital Pharmacy
  • 12.3. Online Pharmacy
  • 12.4. Retail Pharmacy

13. Americas Allergy Immunotherapy Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Allergy Immunotherapy Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Allergy Immunotherapy Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. Stallergenes Greer strengthens Nordic presence with new affiliate for allergen immunotherapy
    • 16.3.2. Australia initiates groundbreaking peanut allergy treatment program for infants
    • 16.3.3. FDA approves Xolair to mitigate allergic reactions from multiple food allergens
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adamis Pharmaceuticals Corporation
  • 2. ALK-Abello, Inc.
  • 3. Allergy Therapeutics PLC
  • 4. Anergis SA
  • 5. ASIT Biotech by DMS Imaging
  • 6. ASIT Biotech SA
  • 7. Biomay AG
  • 8. Biomunex Pharmaceuticals SAS
  • 9. BioSpace, Inc.
  • 10. Circassia Group PLC
  • 11. DBV Technologies SA
  • 12. Eli Lilly and Company
  • 13. F. Hoffmann-La Roche Ltd.
  • 14. GlaxoSmithKline plc
  • 15. HAL Allergy B.V.
  • 16. HollisterStier Allergy by Jubilant Pharma Company
  • 17. Jubilant HollisterStier LLC
  • 18. LETI Pharma, S.L.U.
  • 19. Merck KGaA
  • 20. Mylan N.V. by Viatris Inc.
  • 21. NOVARTIS AG
  • 22. Sanofi S.A
  • 23. Stallergenes Greer International AG
  • 24. Stallergenes Greer Ltd
  • 25. Torii Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. ALLERGY IMMUNOTHERAPY MARKET MULTI-CURRENCY
  • FIGURE 2. ALLERGY IMMUNOTHERAPY MARKET MULTI-LANGUAGE
  • FIGURE 3. ALLERGY IMMUNOTHERAPY MARKET RESEARCH PROCESS
  • FIGURE 4. ALLERGY IMMUNOTHERAPY MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 21. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. AMERICAS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 25. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 30. ALLERGY IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 31. ALLERGY IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ALLERGY IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ALLERGY IMMUNOTHERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY EPICUTANEOUS IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ORAL IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY SUBLINGUAL IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY CAT ALLERGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DOG ALLERGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DUST MITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY EGG ALLERGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY MILK ALLERGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY PEANUT ALLERGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREE NUT ALLERGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY POLLEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DERMAL PATCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DROPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ADJUVANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY NANOTECHNOLOGY-BASED PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY RECOMBINANT ALLERGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGIC ASTHMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ATOPIC DERMATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY URTICARIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 136. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. INDONESIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 144. INDONESIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 145. INDONESIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 146. INDONESIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 147. INDONESIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 153. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 154. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 155. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 156. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. MALAYSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. MALAYSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 162. MALAYSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 163. MALAYSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 164. MALAYSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 165. MALAYSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. MALAYSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. MALAYSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. PHILIPPINES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 171. PHILIPPINES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 172. PHILIPPINES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 173. PHILIPPINES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 174. PHILIPPINES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. PHILIPPINES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. PHILIPPINES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SINGAPORE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SINGAPORE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 180. SINGAPORE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 181. SINGAPORE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 182. SINGAPORE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 183. SINGAPORE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. SINGAPORE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. SINGAPORE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. SOUTH KOREA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 189. SOUTH KOREA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 190. SOUTH KOREA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 191. SOUTH KOREA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 192. SOUTH KOREA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. SOUTH KOREA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. SOUTH KOREA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. TAIWAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. TAIWAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 198. TAIWAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 199. TAIWAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 200. TAIWAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 201. TAIWAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. TAIWAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. TAIWAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. THAILAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. THAILAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 207. THAILAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 208. THAILAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 209. THAILAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 210. THAILAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. THAILAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. THAILAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. VIETNAM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. VIETNAM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 216. VIETNAM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 217. VIETNAM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 218. VIETNAM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 219. VIETNAM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. VIETNAM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. VIETNAM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 232. DENMARK ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. DENMARK ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. DENMARK ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 235. DENMARK ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 236. DENMARK ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 237. DENMARK ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 238. DENMARK ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. DENMARK ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 240. DENMARK ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 241. EGYPT ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. EGYPT ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. EGYPT ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 244. EGYPT ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 245. EGYPT ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 246. EGYPT ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 247. EGYPT ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. EGYPT ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 249. EGYPT ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 250. FINLAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. FINLAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. FINLAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 253. FINLAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 254. FINLAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 255. FINLAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 256. FINLAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. FINLAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 258. FINLAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 259. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 262. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 263. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 264. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 265. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 267. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 268. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 271. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 272. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 273. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 274. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 276. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 277. ISRAEL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. ISRAEL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. ISRAEL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 280. ISRAEL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 281. ISRAEL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 282. ISRAEL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 283. ISRAEL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. ISRAEL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 285. ISRAEL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 286. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 289. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 290. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 291. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 292. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 294. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 295. NETHERLANDS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. NETHERLANDS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. NETHERLANDS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 298. NETHERLANDS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 299. NETHERLANDS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 300. NETHERLANDS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 301. NETHERLANDS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. NETHERLANDS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 303. NETHERLANDS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 304. NIGERIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. NIGERIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. NIGERIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 307. NIGERIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 308. NIGERIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 309. NIGERIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 310. NIGERIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. NIGERIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 312. NIGERIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 313. NORWAY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. NORWAY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 315. NORWAY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 316. NORWAY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 317. NORWAY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 318. NORWAY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 319. NORWAY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. NORWAY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 321. NORWAY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 322. POLAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 323. POLAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 324. POLAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2018-2030 (USD MILLION)
  • TABLE 325. POLAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2018-2030 (USD MILLION)
  • TABLE 326. POLAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2018-2030 (USD MILLION)
  • TABLE 327. POLAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 328. POLAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 329. POLAND ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 20